Evidence map›Paper›PMID 26238117›Full record

ReviewReviews on recent clinical trials2015

The PLCO Biorepository: Creating, Maintaining, and Administering a Unique Biospecimen Resource.

Danielle M Carrick, Amanda Black, John K Gohagan, Asia Khan, Karen Pettit, Craig Williams, Kelly Yu, Susan Yurgalevitch, Wen-Yi Huang, Claire Zhu

Abstract readReview
In one paragraph

Review in Reviews on recent clinical trials, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. The Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial Pathology Tissue Resource.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2016
    Trial
  2. Article
  3. Framework to Select Multi-Cancer Detection Assays in the National Cancer Institute's Vanguard Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Mortality Benefit of a Blood-Based Biomarker Panel for Lung Cancer on the Basis of the Prostate, Lung, Colorectal, and Ovarian Cohort.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Article
  11. Review
  12. Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Conserved serum protein biomarkers associated with growing early colorectal adenomas.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  18. Nutritional metabolomics and breast cancer risk in a prospective study.The American journal of clinical nutrition · 2017
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Danielle M CarrickEpidemiology and Genomics Research Program DCCPS, NCI, NIH, 9609 Medical Center Drive 4E224 Rockville, MD 20850, USA. Danielle.Carrick@nih.gov.
Amanda Black
John K Gohagan
Asia Khan
Karen Pettit
Craig Williams
Kelly Yu
Susan Yurgalevitch
Wen-Yi Huang
Claire Zhu

Funding

Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

Inclusion of biospecimens in population-based studies is an integral part of understanding disease etiology, identifying biomarkers and developing prevention and treatment strategies. The Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial collected, processed and stored biospecimens from participants to create a biorepository of specimens which serves as a useful resource for a broad research community. PLCO collected blood samples from consented screening arm participants at six screening rounds and a buccal sample from consented control arm participants. In addition, formalin-fixed paraffin embedded tumor tissue specimens were collected for participants in both arms for selected cancer sites. Collection of biospecimens at multiple timepoints (i.e. serial samples) and prior to cancer diagnosis, paired with rich epidemiologic and screening data, makes the PLCO collection of biospecimens a uniquely valuable resource. As such, access to the PLCO biorepository is granted to investigators by a rigorous scientific review process and guided by a steering committee which is responsible for developing and implementing the biospecimen use policies. Here, we describe the procedures for biospecimen collection, processing, storage, requisition, and distribution, as well as data management employed in PLCO. We also provide examples of how the biospecimens have been used to advance cancer research and describe relevant lessons learned to help inform cohorts wishing to add or modify biospecimen collection.

Indexed as

Biomarkers, TumorBiomedical ResearchBiopsy, NeedleColorectal NeoplasmsEarly Detection of CancerFemaleHumansLung NeoplasmsMaleMulticenter Studies as TopicNational Cancer Institute (U.S.)NeoplasmsOvarian NeoplasmsProstatic NeoplasmsRandomized Controlled Trials as TopicTissue BanksBiomarkers, Tumor

Identifiers

PMID26238117
PMCPMC6411281

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.